重组人血管内皮抑制素注射液联合NP方案治疗晚期非小细胞肺癌的疗效观察  

Clinical observation of Recombinant Human Endostatin Injection with NP chemotherapy in treating elder advanced non-smaileelllungcancer

作　　者：王巍炜[1] 李高峰[1] 洪志鹏[2] 郭刚[1] 向旭东[1] 陈瑞彬[1] 

机构地区：[1]昆明医学院第三临床附属医院肺癌研究中心,650118 [2]昆明医学院第一临床附属医院

出　　处：《中国医学创新》2010年第8期23-25,共3页Medical Innovation of China

基　　金：云南省教育厅应用基金（09y0173）,云南省科技厅社会发展科技计划应用基础研究项（2009ZC120M）

摘　　要：目的观察了解重组人血管内皮抑制素注射液（恩度）联合NP方案治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。方法37例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊。恩度联合顺铂治疗2～4个周期后评价疗效。结果37例患者中CR4例，PR15例，有效率51．4％（19／37）。中位TTP为6．8个月，1年生存率为43．2％。最主要的毒副反应为白细胞及血小板降低，但均可耐受。结论恩度联合NP方案治疗老年晚期NSCLC有较好疗效，可明显改善患者生存质量，毒副反应轻，易于耐受。Objective To evaluate the clinical effect and toxicity of endostar injection with NP chemotherapy in treating elder advanced non - small cell lung cancer（NSCLC）. Methods 37 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received and were evaluated effect after 2 - 4 cycles. Results Complete remisson （CR） was observrd in 4 cases and PR in 15 cases in 37 cases, the total response rate was 51.4% （ 19/ 37）. Median TIP was 6. 8 months and one years survival rate was 43.2% （ 16/37 ）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. Conclusion The regimen of endostar injection with NP chemotherapy is effective, safe and well - tolerable in the treatment of elder advanced NSCLC.

关 键 词：重组人血管内皮抑素/恩度 非小细胞肺癌 化疗 老年人 

分 类 号：R734[医药卫生—肿瘤]